Impact of supplemental essential phospholipids on treatment outcome and quality of life of patients with psoriasis with moderate severity.

Aim of this study was to evaluate effect of supplemental of essential phospholipids (EPL) on the treatment efficacy in patients with moderate psoriasis. One hundred and thirty-two subjects over 18 years of age with diagnosed psoriasis participated in this study. Patients were randomly assigned two treatment groups. Two types of treatment were used for the treatment of the patients. First group of patients received conventional treatment which included systemic immunosuppressant, antihistamine, calcium gluconate, and topical salicylic acid. Second group (n = 67) received same treatment with supplemental EPL. Data was comprised of age, gender, psoriasis area and severity index (PASI) and dermatological life quality index (DLQI) scores, other clinical/laboratory characteristics including TNF-α, IL-1α, IL-2, INF-γ, IL-10, and TGF-β. All measurements were done before and after treatments. After treatment in the treatment groups the PASI scores decreased to 4.5 (SD ± 2.66) and 2.09 (SD ± 1.09) respectively. The observed difference was statistically significant (p < 0.001). Change of PASI score was greater in group II on average by 2.81 (SD ± 0.38). After treatment in both groups the DLQI scores decreased to 4.42 (SD ± 1.23) and 3.91 (SD ± 0.34), respectively. The observed difference was statistically significant (p < 0.001). Change of DLQI score was greater in group II on average by 4.29 (SD ± 0.44). We can state that addition of EPL to the standard treatment can improve treatment outcomes and quality of life in patients with moderate psoriasis.